After Hours: Biosimilar Whiskey

As high-end whisky can take decades to develop and total to thousands of dollars per bottle, a novel process created by Sarfaraz Niazi, adjunct professor of biopharmaceutical sciences and advisory board member for the Center for Biosimilars®, seeks to circumvent both time and cost by replicating the biosimilar approach to therapeutic drugs to that of whisky. Dr. Niazi speaks with The American Journal of Managed Care® on the distillation process, how the biobetter whiskies compared with their reference products, and future considerations for the alcohol industry.